New Atlas

First oral GLP-1 cuts cardiovascular risk by 14% – and it's now FDA-approved

There's still no oral GLP-1 pill dedicated to treating obesity, however, Novo Nordisk has filed a separate case to the FDA seeking approval for its once-daily oral semaglutide (Wegovy). This decision ...

Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy(R) in a pill*) at ObesityWeek(R) 2025, including demonstrated reductions in cardiovascular risk factors

The MarketWatch News Department was not involved in the creation of this content.-- Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associate ...

NOVO NORDISK INC.: Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy in a pill*) at ObesityWeek 2025, including demonstrated reductions in ...

Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associated with improvements in blood sugar control and cardiovascular (CV) risk factors across multiple ...